153 related articles for article (PubMed ID: 38443891)
1. Chemotherapy re-use versus anti-angiogenic monotherapy as the third-line treatment of patients with metastatic colorectal cancer: a real-world cohort study.
Duan J; Zhu L; Shi Y; Wang W; Wang T; Ning T; Zhang L; Bai M; Li H; Liu R; Ge S; Wang X; Yang Y; Ji Z; Wang F; Sun Y; Ba Y; Deng T
BMC Cancer; 2024 Mar; 24(1):302. PubMed ID: 38443891
[TBL] [Abstract][Full Text] [Related]
2. [The efficacy of chemotherapy re-challenge in third-line setting for metastatic colorectal cancer patients: a real-world study].
Duan JJ; Ning T; Bai M; Zhang L; Li HL; Liu R; Ge SH; Wang X; Yang YC; Ji Z; Wang FX; Sun YS; Ba Y; Deng T
Zhonghua Zhong Liu Za Zhi; 2023 Nov; 45(11):967-972. PubMed ID: 37968083
[No Abstract] [Full Text] [Related]
3. Third-line treatment patterns and clinical outcomes for metastatic colorectal cancer: a retrospective real-world study.
Deng T; Duan J; Bai M; Zhang L; Li H; Liu R; Ning T; Ge S; Wang X; Yang Y; Ji Z; Wang F; Ba Y
Ther Adv Chronic Dis; 2023; 14():20406223231197311. PubMed ID: 37720594
[TBL] [Abstract][Full Text] [Related]
4. Cetuximab as third-line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild-type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trials.
Martini G; Ciardiello D; Famiglietti V; Rossini D; Antoniotti C; Troiani T; Napolitano S; Esposito L; Latiano TP; Maiello E; Del Re M; Lonardi S; Aprile G; Santini D; Masi G; Avallone A; Normanno N; Pietrantonio F; Pinto C; Ciardiello F; Cremolini C; Martinelli E
Cancer Med; 2023 Apr; 12(8):9392-9400. PubMed ID: 36880426
[TBL] [Abstract][Full Text] [Related]
5. Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM).
Ciardiello D; Chiarazzo C; Famiglietti V; Damato A; Pinto C; Zampino MG; Castellano G; Gervaso L; Zaniboni A; Oneda E; Rapisardi S; Bordonaro R; Zichi C; De Vita F; Di Maio M; Parisi A; Giampieri R; Berardi R; Lavacchi D; Antonuzzo L; Tamburini E; Maiorano BA; Parrella P; Latiano TP; Normanno N; De Stefano A; Avallone A; Martini G; Napolitano S; Troiani T; Martinelli E; Ciardiello F; De Vita F; Maiello E
ESMO Open; 2022 Oct; 7(5):100567. PubMed ID: 35994791
[TBL] [Abstract][Full Text] [Related]
6. Efficacy, safety and genomic analysis of SCT200, an anti-EGFR monoclonal antibody, in patients with fluorouracil, irinotecan and oxaliplatin refractory RAS and BRAF wild-type metastatic colorectal cancer: a phase Ⅱ study.
Yang L; Zhang W; Fan N; Cao P; Cheng Y; Zhu L; Luo S; Zong H; Bai Y; Zhou J; Deng Y; Ba Y; Liu T; Aili M; Yin X; Gu K; Dai G; Ying J; Shi J; Gao Y; Li W; Yu G; Xie L; Gai W; Wang Y; Meng P; Shi Y
EBioMedicine; 2024 Feb; 100():104966. PubMed ID: 38217945
[TBL] [Abstract][Full Text] [Related]
7. The efficacy and safety of immune checkpoint inhibitors combined with chemotherapy or anti-angiogenic therapy as a second-line or later treatment option for advanced non-small cell lung cancer: a retrospective comparative cohort study.
Chen B; Wang J; Pu X; Li J; Wang Q; Liu L; Xu Y; Xu L; Kong Y; Li K; Xu F; Liang S; Cardona AF; Wu L
Transl Lung Cancer Res; 2022 Oct; 11(10):2111-2124. PubMed ID: 36386462
[TBL] [Abstract][Full Text] [Related]
8. Regorafenib monotherapy or combined with an immune-checkpoint inhibitor as later-line treatment for metastatic colorectal cancer: a multicenter, real-world retrospective study in China.
Qu W; Liu Z; Chen X; Liu B; Zhao Y; Yan H; Qu X; Li S; Zang A; Sun Y; Zhu L; Zhou A
BMC Cancer; 2024 Jan; 24(1):22. PubMed ID: 38166647
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the efficacy and safety of fruquintinib and regorafenib in the treatment of metastatic colorectal cancer: A real-world study.
Deng YY; Zhang XY; Zhu PF; Lu HR; Liu Q; Pan SY; Chen ZL; Yang L
Front Oncol; 2023; 13():1097911. PubMed ID: 36937443
[TBL] [Abstract][Full Text] [Related]
10. PD-1/PD-L1 inhibitors plus anti-angiogenic agents with or without chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy as second or later-line treatment for patients with advanced non-small cell lung cancer: A real-world retrospective cohort study.
Chen S; Wei H; Zhao W; Jiang W; Ning R; Zhou S; Tan L; Wang H; Su C; He J; Zeng A; Zhao Y; Yu Q
Front Immunol; 2022; 13():1059995. PubMed ID: 36569915
[TBL] [Abstract][Full Text] [Related]
11. High DCR and Better Survival in Patients with Advanced or Metastatic Gastric Cancer Receiving Anti-Angiogenic TKI plus Chemotherapy: A Real-World Study.
Nie C; Lv H; Chen B; Xu W; Wang J; Wang S; Liu Y; He Y; Zhao J; Chen X
Technol Cancer Res Treat; 2023; 22():15330338221150561. PubMed ID: 36632666
[No Abstract] [Full Text] [Related]
12. Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer.
Taşçı EŞ; Oyan B; Sönmez Ö; Mutlu AU; Atcı MM; Sakin A; Öner İ; Çınkır HY; Eryılmaz MK; Çağlayan D; Balçık OY; Paksoy N; Karabulut S; Salim DK; Bilir C; Özen M; Özçelik M; Arıcan A; Akagündüz B; İnal A; Aydın D; Özer L; Gülmez A; Turhal NS; Esen SA; Algın E; Akbaş S; İriağaç Y; Şakalar T; Ünal Ç; Er Ö; Seçmeler Ş; Bozkurt M
BMC Cancer; 2024 Jan; 24(1):16. PubMed ID: 38166764
[TBL] [Abstract][Full Text] [Related]
13. Differential Efficacy of Targeted Monoclonal Antibodies in Left-Sided Colon and Rectal Metastatic Cancers.
Kodama H; Masuishi T; Wakabayashi M; Nakata A; Kumanishi R; Nakazawa T; Ogata T; Matsubara Y; Honda K; Narita Y; Taniguchi H; Kadowaki S; Ando M; Muro K
Clin Colorectal Cancer; 2023 Sep; 22(3):298-306. PubMed ID: 37270357
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of irinotecan combined with raltitrexed or irinotecan monotherapy for salvage chemotherapy of esophageal squamous cell cancer: A prospective, open label, randomized phase II study.
Dai X; Tao L; Wang J; Wu W; Bian W; Dai X; Chen S
Cancer Med; 2023 Aug; 12(15):16108-16118. PubMed ID: 37325938
[TBL] [Abstract][Full Text] [Related]
15. Real-World Activity and Safety of Trifluridine-Tipiracil Plus Bevacizumab Therapy in Patients with Refractory Metastatic Colorectal Cancer.
Arrichiello G; Perrone A; Napolitano S; Martini G; De Falco V; Incoronato P; Laterza MM; Facchini G; Famiglietti V; Nacca V; Paragliola F; Napolitano R; Suarato G; Nicastro A; Martinelli E; Ciardiello D; Ciardiello F; Troiani T
Target Oncol; 2022 Nov; 17(6):635-642. PubMed ID: 36239883
[TBL] [Abstract][Full Text] [Related]
16. Third-line treatment options in metastatic pancreatic cancer patients: a real-world study.
Lu HR; Zhu PF; Deng YY; Chen ZL; Yang L
Front Oncol; 2023; 13():1251258. PubMed ID: 37810973
[TBL] [Abstract][Full Text] [Related]
17. RETRO-TAS, a Retrospective Observational Study of Trifluridine/Tipiracil in Chemorefractory Metastatic Colorectal Cancer.
Koumarianou A; Ntavatzikos A; Symeonidis D; Vallilas C; Giannakakou M; Papaxoinis G; Xynogalos S; Boukovinas I; Demiri S; Kampoli K; Oikonomopoulos G; Samantas E; Res E; Androulakis N; Vourli G; Souglakos I; Karamouzis M
Biomedicines; 2023 Apr; 11(5):. PubMed ID: 37238938
[TBL] [Abstract][Full Text] [Related]
18. Patient demographics and management landscape of metastatic colorectal cancer in the third-line setting: Real-world data in an australian population.
Min ST; Roohullah A; Tognela A; Jalali A; Lee M; Wong R; Shapiro J; Burge M; Yip D; Nott L; Zimet A; Lee B; Dean A; Steel S; Wong HL; Gibbs P; Lim SH
Asia Pac J Clin Oncol; 2022 Apr; 18(2):e56-e63. PubMed ID: 33870631
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy strategies for EGFR-mutated advanced NSCLC after EGFR tyrosine-kinase inhibitors failure.
Li X; Huang H; Sun Y; Jiang Q; Yu Y
Front Oncol; 2023; 13():1265236. PubMed ID: 37869096
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of irinotecan, oxaliplatin, and capecitabine (XELOXIRI) regimen with or without targeted drugs in patients with metastatic colorectal cancer: a retrospective cohort study.
Liu X; Ou K; Ma X; Gao L; Wang Q; Zhang H; Yang L
BMC Cancer; 2022 Jul; 22(1):807. PubMed ID: 35864467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
